Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data

  • 1,
  • 1,
  • 1, 2,
  • 3,
  • 4,
  • 4,
  • 3 and
  • 1, 5Email author
BMC Infectious Diseases201515:559

https://doi.org/10.1186/s12879-015-1297-x

©  Oikonomou et al. 2015

  • Received: 20 June 2015
  • Accepted: 27 November 2015
  • Published:
Open Peer Review reports

Abstract

Background

Colistin-resistant/carbapenem-resistant Acinetobacter baumannii is a significant challenge for antibiotic treatment and infection control policies. Since 2012, in Central Greece an increase of colistin/pan- resistant A. baumannii has occurred, indicating the need for further analysis.

Methods

A total of 86 colistin-resistant/carbapenem-resistant out of 1228 A. baumannii clinical isolates, consecutively collected between 2012 and 2014 in a tertiary Greek hospital of Central Greece, as well as one environmental isolate from surveillance cultures were studied. Molecular typing and mechanisms of resistance to colistin and to carbapenems were assessed, whereas, epidemiological and clinical data of the patients were reviewed.

Results

During the study period, the rate of colistin resistance gradually increased and reached 21.1 % in 2014. All colistin-resistant/carbapenem-resistant A. baumannii belonged to 3LST ST101 clone that corresponds to the international clonal lineage II. Carbapenem resistance was associated with the presence of bla oxa-23-like, while resistance to colistin probably correlated with G54E and R109H amino acid substitutions in PmrA and PmrC, respectively.

Conclusions

Epidemiological data of the patients indicated that the first detection of colistin-resistant/carbapenem-resistant ST101 clone in the University Hospital of Larissa (UHL) was associated with a patient who previously had received colistin, while, the movement of the infected patients into the hospital probably resulted to its spread.

Keywords

  • A. baumannii
  • Colistin resistance
  • ST101
  • Greece

Background

Acinetobacter baumannii isolates are recognized as major nosocomial pathogens; their ability to survive in dry conditions and their resistance to disinfectants allow these microorganisms to survive in the hospital environment [1, 2]. Carbapenems, which have been used to treat infections caused by A. baumannii, are gradually being inactivated by the emergence of resistant strains [3]. Various mechanisms involved in carbapenem-resistance of A. baumannii include production of carbapenemases, modification of antibiotic targets, overexpression of efflux pumps and loss of porins [4]. Carbapenem-resistant strains that are also simultaneously resistant to various, non-beta-lactams antimicrobial agents pose important therapeutic problem, due to the limited number of efficacious drugs [5]. Colistin and tigecycline are often the only treatment options for multiresistant A. baumannii infections but resistance to both agents has recently been described, with colistin resistance scattered worldwide [6–13].

Colistin is rapidly bactericidal for Gram-negative bacteria, interacting with the lipid A components of lipopolysaccharide (LPS), resulting in the disorganization of the outer membrane of bacteria [14]. However, the wide usage of colistin, against carbapenem-resistant multiresistant A. baumannii led to the development of resistance [15]. In A. baumannii, colistin-resistance is mediated by complete loss of LPS production via mutations within the genes (lpxA, lpxC and lpxD) of the lipid A biosynthesis pathway or by modification of lipid A components of LPS via mutations in the pmrA and pmrB genes of the two-component regulatory system and pmrC that codes a lipid A phosphoethanolamine transferase [16–20].

In the University Hospital of Larissa (UHL), that is the main tertiary hospital of Thessaly (Central Greece) serving a region of 1,200,000 habitants, enhanced systemic surveillance resulted to a decrease of carbapenem-resistant A. baumannii between 2012 and 2014 (2.6 cases in 2012 vs 2.1 cases in 2013 and 1.9 cases in 2014 respectively, per 1,000 patient-days). However, despite this encouraging record, increased rate of colistin-resistance among A. baumannii was observed. Aim of this study was to determine the molecular characteristics of the isolates (mechanisms of resistance and molecular typing) and to describe the epidemiological traits.

Methods

Clinical isolates, identification and susceptibility testing

From January 2012 to December 2014, a total of 1228 consecutive A. baumannii isolates (494 in 2012, 407 in 2013 and 327 in 2014) were recovered from clinical samples taken as part of standard care of an equal number of individual patients admitted to the University Hospital of Larissa, Thessaly (Central Greece). Only the first isolate from each patient was included in this study. In addition, ten environmental isolates, recovered during 2014 from 300 environmental cultures (100 from sink, 50 from patient beds, 50 from cupboards and 100 from handle of door) from various wards of UHL, were also included. Cotton-tipped swabs were moistened with sterile saline and surfaces vigorously scrubbed. Potential fomites included ventilator control panel and sensor, bed rails, supply cabinets, computer keyboards and mice, curtains, air vents, door handles, supply carts and mattresses.

Identification and susceptibility testing

Identification and antimicrobial susceptibility testing of bacterial isolates was performed by the VITEK-2 system (bioMérieux, Marcy l’Étoile, France). Determination of MICs to colistin and fosfomycin were assessed by the Etest method (bioMérieux, Marcy l’Étoile, France), while, the interpretation was in accordance with the CLSI breakpoints [21]. For isolates with MICs to colistin > = 4 mg/L confirmation was done by broth microdilution method according to CLSI guidelines [22]. Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as control strains [23].

Molecular assays

All A. baumannii, clinical and environmental, that were classified as colistin-resistant using CLSI criteria (MICs > =4 mg/L), were further analyzed for molecular typing and the underlying mechanisms of resistance to colistin and to β-lactams.
  1. a.

    Molecular typing

     
Molecular typing was done using primers for amplifying and sequencing ompA, csuE and bla OXA-51-like gene fragments as described previously [24].
  1. b.

    Mechanisms for colistin and carbapenem resistance

     

The strains were screened for the presence of mutations in the lpxA, lpxC, lpxD and pmrCAB genes, which have been associated with the emergence of colistin resistance. After DNA extraction by using the Quick-gDNA™ MiniPrep kit (ZYMO RESEARCH Corp., USA), the genes were amplified by polymerase chain reaction (PCR) as described previously [16, 19], and the PCR amplicons were sequenced on both DNA strands using an ABI3730 DNA sequencer (Applied Biosystems, Warrington, United Kingdom). Nucleotide sequences of lpxA, lpxC, lpxD and pmrCAB genes from colistin-resistant isolates were compared with the respective sequences obtained from three colistin-susceptible (MICs to colistin 0.25 mg/ml,), belonging to the same clone as the resistant strains, and with that of the reference strain ATCC17978 (GenBank Accession Number CP000521). The detection of bla IMP, bla VIM, bla GIM,, bla SIM, bla KPC, bla NDM-1 and bla oxa-48, as well as bla oxa-23-like bla oxa-23-like, bla oxa-24-like, bla oxa-51-like, bla oxa-58-like, was done by PCR as described elsewhere [25].

Demographic data of patients

Demographic data (age, sex etc.) and clinical data of patients diagnosed with colistin- resistant A. baumannii infection were reviewed regarding their current and previous hospitalizations, previous antibiotic therapy, sites of infection or colonization, comorbidities, outcome etc.

Ethics

Before obtaining the clinical information, all patients sign the inform consent, while, approval was received by the Ethics Committee of the UHL that is represented by the Infection Control Committee (number of permission 1334).

Results

During the study period, 1116 carbapenem-resistant A. baumannii (CR A. baumannii) were isolated. The rate of carbapenem resistance was 93 % in 2012, 88 % in 2013 and 91 % in 2014, respectively, while, all carbapenem-resistantisolates had MICs to imipenem and meropenem >256 mg/L. On the other hand, the rate of colistin resistance was 1 % in 2012, 2.9 % in 2013 and 21.1 % in 2014, while, an increase in MICmean value, MIC50 and MIC90 was observed from year to year. In more details, the MICmean value, MIC50 and MIC90 were 0.76, 0.48 and 0.49 mg/L in 2012, 1.44, 0.49 and 0.62 mg/L in 2013 and 6.4, 0.65 and 3.3 mg/L in 2014, respectively.

Totally, eighty six A.baumannii clinical isolates were identified as colistin- and carbapenem-resistant, with the MICs of colistin ranging from 16 to 64 mg/L; they were recovered from clinically significant samples (blood, bronchial secretions etc.) from different patients of the UHL and all were associated with infection according to criteria [26–28]. Five and 12 of them were collected in 2012 and in 2013, respectively, while the remaining 69 A. baumannii were eventually collected during 2014. All were pan-resistant expressing simultaneously resistance to fluoroquinolones and aminoglycosides, whereas, 13 and 40 % of them were susceptible to tigecycline and fosfomycin, respectively. No decrease in resistance levels of other antimicrobial agents was observed. On the other hand, the environmental A. baumannii were carbapenem-resistant, but only one was resistant to colistin.

Molecular characterization of the isolates (86 clinical and one environmental) revealed that all belonged to 3LST ST101, that corresponds to the international clonal lineage II, and carried the bla OXA-23 gene being responsible for high level resistance to carbapenems (MIC >256 mg/L). To investigate the mechanisms of the observed high rate of resistance to colistin, all colistin-resistant isolates were screened for the presence of mutations in the lpxACD and pmrCAB genes. Sequencing of lpx genes revealed the presence of four amino acid substitutions (LpxA: Y131H; LpxC:C120R + N287D; LpxD:E117K) in all colistin-resistant and colistin-susceptible isolates, compared to the sequences of the A. baumannii ATCC 17978. On the other hand, sequencing of the pmrCAB genes detected two different patterns of amino acid substitutions, that were not detected in the ATCC 17978 strain, (i) PmrB:A138T + A226V + A444V; PmrC:F150L + I212V + R332K + A354S + K515T (pattern A; GenBank accession number KR024312) among colistin-susceptible ST101 A. baumannii and (ii) PmrA:G54E; PmrB:A138T + A226V + A444V; PmrC:R109H + F150L + I212V + R332K + A354S + K515T (pattern B; GenBank accession number KR024313) among colistin resistant ST101 A. baumannii. This finding apparently underlines the involvement of PmrA: G54E and PmrC: R109H substitutions in the development of colistin resistance in A. baumannii isolates of ST101. None of the substitutions, found in lpxACD and pmrCAB genes, have been previously reported.

According to the demographic data, the index case was a 62 year- old man, hospitalized in the Department of Internal Medicine (DIM) for a cellulitis in the abdominal area, and empirically treated with intravenous colistin and daptomycin; the tenth day of treatment, on 7th January 2012, the patient presented fever and the blood culture obtained recovered a colistin/carbapenem resistant A. baumannii. Few days later, two other DIM patients were found to be infected by this microorganism, while, on September, a fourth DIM patient, admitted from a Long Term Care Facility (LTCR) of Thessaly, was diagnosed with pyelonephritis due to this strain. Unfortunately, the patient deteriorated and was transferred to the Intensive Care Unit (ICU) of UHL; 10 days later, an ICU patient, who had never been treated with colistin, developed VAP (ventilator associated pneumonia) due to colistin/carbapenem resistant A. baumannii. After the first detection of this pan-resistant microorganism, the Infection Control Committee of UHL applied enhanced hygiene and environmental cleaning measures. From October 2012 to March 2013, no colistin-resistant A. baumannii were detected in our hospital. However, between April and June 2013, two small outbreaks took place in both the ICU and the DIM, including five and seven patients respectively. Nevertheless, despite the strict prevention measures, during 2014 several colistin/carbapenem resistant A. baumannii., have been isolated in various wards of UHL. Fosfomycin and or tigecycline were mainly used for the treatment of these patients. Clinical information and the outcome of the patients are described in Table 1.
Table 1

Clinical characteristics of the patients

Sex (Male)

48 %

Age (Years)

67 (59,74)

Days after admit to culture

10 (6, 17)

Prior use of colistin within 6 months

23 %

Hospitalization within 6 months

31 %

Prior use of colistin during hospitalization

41 %

ICU stay

62 %

Presence of medical devices

68 %

Comorbidities

Chronic Heart disease

31 %

Chronic Lung disease

10 %

Diabetes Mellitus

10 %

Chronic Renal failure

10 %

Neurological disease

17 %

Chronic Liver Disease

6 %

Malignancy

3 %

Source of infection

Blood Stream Infection

50 %

Pneumonia

42 %

Ventriculitis

6 %

other

2 0025

Data are presented as median (25 %, 75 % quartiles) or n (%)

Discussion

Acinetobacter baumannii is a particularly challenging pathogen because it is associated with a high degree of resistance, and it is difficult to eliminate its environmental reservoir in healthcare settings [29]. Carbapenems are considered first-line agents for the treatment of A. baumannii infections, and therefore the rise of infections due to carbapenem-resistant strains is of particular concern [30]. Additionally, carbapenem-resistant A. baumannii isolates are often susceptible to only 1 or 2 agents, making them extensively drug-resistant (XDR) pathogens by definition [30]. The incidence of XDR A. baumannii infections is continually rising [31–33]. For severe XDR A. baumannii infections, polymyxins are frequently used, and are considered by most to be the drugs of choice [34]. Today, colistin-resistant/carbapenem-resistant pan-resistant A. baumannii, spread and cause nosocomial outbreaks [35–37].

In UHL such as in all Greek hospitals, the rate of carbapenem-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii is very high, resulting to a wide usage of colistin [38]. Between 2012 and 2014, despite the strict prevention measures in our hospital, the rate of colistin-resistant/pan-resistant A. baumannii dramatically increased. All these isolates belonged to 3LST ST101, a clone that predominates for long time in UHL [39]. We note that, since 2011, all colistin-susceptible carbapenem-resistant A. baumannii belong to clone ST101 as those exhibiting resistance. We suppose that under the selective pressure of colistin this clone became resistant and then, it was spread from patient to patient. Recently, Mavroidi et al., reported two 3LST ST 101 colistin-resistant A. baumannii recovered from patients hospitalized in a tertiary Greek hospital in Athens [40].

In our study, the prevalence of colistin-resistant A. baumannii in the environmental cultures was low. Numerous studies have documented the presence of Acinetobacter spp in the hospital environment, but rates of positive cultures may vary widely, depending on the epidemiological setting and on the places of collection [1, 41]. Our environmental A. baumannii strains originated mainly from the patient beds and the bedside cupboards indicating that these places present risk for nosocomial outbreaks. The ability of this microorganism to form biofilms blocks its eradication from the surfaces by the cleaning and promotes its persistence in the hospital setting [42].

Previous studies have shown that resistance to colistin is associated with mutations in pmrB gene [18, 19, 35, 37]. Interestingly, in our strains, colistin resistance was correlated with mutations in pmrA and pmrC. However, a further study is necessary to prove the involvement of the G54E (PmrA) and R109H (PmrC) amino acid substitutions in the development of colistin resistance in A. baumannii, and to characterize the impact of the latter substitutions in the modification of lipid A components. Of note was that, acquisition of colistin resistance did not alter resistance to other antibiotics, which is in agreement with previous studies demonstrating that, in contrast to Lpx alterations, mutations in pmrCAB do not result in increased susceptibility to other antimicrobials [16, 35].

The UHL is the main tertiary care unit of Central Greece and admits patients coming from different parts of the area; therefore, there is a great risk of spreading this pan-resistant clone in the entire region, concerning that this clone consist part of the microbiota of the hospital. The first four months of 2015, the rate of colistin/carbapenem resistant A. baumannii continued rising dramatically and reached to 52 % (data not shown). In order to limit this dissemination, all patients before their discharge are tested if they are colonized with colistin-resistant A. baumannii. In addition, unnecessary transfer of patients from the surrounding hospitals to UHL stopped. Until now, only few colistin-resistant strains have been isolated from the local hospitals and LTCFs of Central Greece.

Conclusions

In the present study, from 2012 till 2014, a significant increase of colistin-resistant/carbapenem-resistant A. baumannii in a tertiary care hospital in central Greece was observed. All isolates belonged to 3LST ST101 clone and their resistance to carbapenems and to colistin was associated with the production of OXA-23-like carbapenem-hydrolyzing class D β-lactamase and with mutations in pmrA and pmrC genes, respectively. Epidemiological data of the patients indicated that the first detection of colistin-resistant/carbapenem-resistant ST101 clone in UHL was associated with a patient who had previously received colistin, while, the movement of the infected patients into the hospital probably resulted to its spread.

Abbreviations

DIM: 

Department of Internal Medicine

ICU: 

Intensive Care Unit

LST: 

locus sequence typing

LTCF: 

Long Term Care Facility

ST: 

sequence type

UHL: 

University Hospital of Larissa

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Microbiology, University Hospital of Larissa, Larissa, Greece
(2)
Faculty of Medicine and University Hospital in Plzen, Charles University in Prague, Plzen, Czech Republic
(3)
Department of Medicine, Medical School, University of Thessaly, Larissa, Greece
(4)
Department of Critical Care, Medical School, University of Thessaly, Larissa, Greece
(5)
Department of Microbiology, Medical School, University of Thessaly, Larissa, Greece

References

  1. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical and epidemiological features. Clin Microbiol Rev. 1996;9:148–65.PubMed CentralPubMedGoogle Scholar
  2. Durante-Mangoni E, Zarrilli R. Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. Future Microbiol. 2011;6:407–22.View ArticlePubMedGoogle Scholar
  3. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51:3471–84.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12:826–36.View ArticlePubMedGoogle Scholar
  5. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5:939–51.View ArticlePubMedGoogle Scholar
  6. Stein A, Raoult D. Colistin: an antimicrobial for the 21st century? Clin Infect Dis. 2002;35:901–2.View ArticlePubMedGoogle Scholar
  7. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 2012;10:917–34.View ArticlePubMedGoogle Scholar
  8. Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60:1295–303.PubMedGoogle Scholar
  9. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004). Clin Microbiol Infect. 2006;12:315–21.View ArticlePubMedGoogle Scholar
  10. Rodriguez CH, Bombicino K, Granados G, Nastro M, Vay C, Famiglietti A. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis. 2009;65:188–91.View ArticlePubMedGoogle Scholar
  11. Park YK, Choi JY, Jung SI, Park KH, Lee H, Jung DS, et al. Two distinct clones of carbapenem resistant Acinetobacter baumannii isolates from Korean hospitals. Diagn Microbiol Infect Dis. 2009;64:389–95.View ArticlePubMedGoogle Scholar
  12. Agodi A, Voulgari E, Barchitta M, Quattrocchi A, Bellocchi P, Poulou A, et al. Spread of a carbapenem-and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two Sicilian hospitals. J Hosp Infect. 2014;86:260–6.View ArticlePubMedGoogle Scholar
  13. Choi JY, Ko EA, Kwon KT, Lee S, Kang CI, Chung DR, et al. Acinetobacter sp. isolates from emergency departments in two hospitals of South Korea. J Med Microbiol. 2014;63:1363–8.View ArticlePubMedGoogle Scholar
  14. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol. 2014;5:643. 26.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Pogue JM, Cohen DA, Marchaim D. Editorial commentary: polymyxin-resistant Acinetobacter baumannii: urgent action needed. Clin Infect Dis. 2015;60:1304–7.PubMed CentralPubMedGoogle Scholar
  16. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010;54:4971–7.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55:3022–4.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two component system. Antimicrob Agents Chemother. 2009;53:3628–34.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother. 2011;55:3370–9.PubMed CentralView ArticlePubMedGoogle Scholar
  20. Park YK, Lee JY, Ko KS. Transcriptomic analysis of colistin-susceptible and colistin-resistant isolates identifies genes associated with colistin resistance in Acinetobacter baumannii. Clin Microbiol Infect. 2015;21(8):e1–7. doi:10.1016/j.cmi.2015.04.009. 765.Google Scholar
  21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-First Information Supplement, CLSI document M100-S21. Wayne, PA: CLSI; 2012.Google Scholar
  22. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility testing; 23rd International Supplement, CLSI document M100-S23. Wayne, PA: CLSI; 2013.Google Scholar
  23. Jones RN, Anderegg TR, Swenson JM, Quality Control Working Group. Quality control guidelines for testing gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. J Clin Microbiol. 2005;43:925–7.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Turton JF, Gabriel SN, Valderrey C, Kaufmann ME, Pitt TL. Use of sequence-based typing and multiplex PCR to identify clonal lineages of outbreak strains of Acinetobacter baumannii. Clin Microbiol Infect. 2007;13:807–15.View ArticlePubMedGoogle Scholar
  25. Lee K, Yum JH, Yong D, Lee HM, Kim HD, Docquier JD, et al. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother. 2005;49:4485–91.PubMed CentralView ArticlePubMedGoogle Scholar
  26. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.View ArticleGoogle Scholar
  27. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control. 1988;16:128–40.View ArticlePubMedGoogle Scholar
  28. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infection in the acute care setting. Am J Infect Control. 2008;36:309–32.View ArticlePubMedGoogle Scholar
  29. Weber DJ, Rutala WA, Miller MB, Huslage K, Sickbert-Bennett E. Role of hospital surfaces in the transmission of emerging health care-associated pathogens: norovirus, Clostridium difficile, and Acinetobacter species. Am J Infect Control. 2010;38:S25–33.View ArticlePubMedGoogle Scholar
  30. Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 2014;74:1315–33.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Solomennyi A, Goncharov A, Zueva L. Extensively drug-resistant Acinetobacter baumannii belonging to the international clonal lineage I in a Russian burn intensive care unit. Int J Antimicrob Agents. 2015;45:525–8.View ArticlePubMedGoogle Scholar
  32. Teo J, Lim TP, Hsu LY, Tan TY, Sasikala S, Hon PY, et al. Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. Antimicrob Resist Infect Control. 2015;4:2.PubMed CentralView ArticlePubMedGoogle Scholar
  33. Azimi L, Talebi M, Pourshafie MR, Owlia P, Rastegar LA. Characterization of carbapenemases in extensively drug resistance Acinetobacter baumannii in a burn care center in Iran. Int J Mol Cell Med. 2015;4:46–53.PubMed CentralPubMedGoogle Scholar
  34. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2005;25:11–25.View ArticlePubMedGoogle Scholar
  35. Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, et al. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J Infect Dis. 2013;208:1142–51.View ArticlePubMedGoogle Scholar
  36. Valencia R, Arroyo LA, Conde M, Aldana JM, Torres MJ, Fernández-Cuenca F, et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol. 2003;30:257–63.View ArticleGoogle Scholar
  37. Kim Y, Bae IK, Lee H, Jeong SH, Yong D, Lee K. In vivo emergence of colistin resistance in Acinetobacter baumannii clinical isolates of sequence type 357 during colistin treatment. Diagn Microbiol Infect Dis. 2014;79:362–6.View ArticlePubMedGoogle Scholar
  38. WHONET Greece (last update 17-12-2014). http://www.mednet.gr/whonet.
  39. Liakopoulos A, Miriagou V, Katsifas EA, Karagouni AD, Daikos GL, Tzouvelekis LS, et al. Identification of OXA-23-producing Acinetobacter baumannii in Greece 2010 to 2011. Euro Surveill. 2012;17:11.Google Scholar
  40. Mavroidi A, Likousi S, Palla E, Katsiari M, Roussou Z, Maguina A, et al. Molecular identification of tigecycline- and colistin-resistant carbapenemase-producing Acinetobacter baumannii from a Greek hospital from 2011 to 2013. J Med Microbiol. 2015;64:993–7.View ArticlePubMedGoogle Scholar
  41. Crombach WH, Dijkshoorn L, van Noort-Klaassen M, Niessen J, van Knippenberg-Gordebeke G. Control of an epidemic spread of a multi-resistant strain of Acinetobacter calcoaceticus in a hospital. Intensive Care Med. 1989;15:166–70.View ArticlePubMedGoogle Scholar
  42. Luo TL, Rickard AH, Srinivasan U, Kaye KS, Foxman B. Association of blaOXA-23 and bap with the persistence of Acinetobacter baumannii within a major healthcare system. Front Microbiol. 2015;6:182.PubMed CentralPubMedGoogle Scholar

Copyright

© Oikonomou et al. 2015

Advertisement

BMC Infectious Diseases

ISSN: 1471-2334

Contact us